Migraine Prevention Therapy: Avoiding Overuse of Medications

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Burden of Migraine

When to Consider Prevention

Use of Migraine Medication and Healthcare Resources: AMPP Study

Current Evidence-Based Migraine Prevention Treatments

Behavioral Preventive Therapy and Pharmacologic Treatment Adherence

Four Issues Affecting Current Prevention Therapy

Natural Fluctuations Between Episodic and Chronic Migraine: CaMEO

Risk Factors for Progression From Episodic to Chronic Migraine

ICHD-3 Beta Criteria: Medication Overuse Headache

Medication Use and Risk of Transformation From Episodic to Chronic Migraine

Chronic Migraine and Medication Overuse Headache

Combination Behavioral and Pharmacologic Treatment in Medication Overuse

Future of Migraine Prevention: CGRP as a Treatment Target

CGRP Receptor Blockers: Gepants

mAbs Targeting the CGRP Pathway

The 4 Anti-CGRP mAbs: Status Overview

Secondary Endpoints and Improvement in Function: Example of Erenumab

Anti-CGRP mAbs: Trial Endpoints

Reduction in Monthly Migraine Days in Episodic Migraine: Erenumab and Galcanezumab

Decrease in Monthly Migraine Days and Migraine Symptoms: Fremanezumab

Eptinezumab in Episodic Migraine and 75% Responder Rates in Chronic Migraine

Erenumab in Chronic Migraine

Safety of Anti-CGRP mAbs: Similar to Placebo

Reconsidering the 4 Issues Affecting Current Prevention Therapy: Anti-CGRP mAbs

Future of Migraine Prevention

Abbreviations